Akero Therapeutics, Inc.
DelistedCIK 1744659fmd_0TZFZDR9FSK8GKPQM4B2W1R4BJManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Sep 30, 2025, 31 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|
| Research and development | 12 | 37 | 65 | 82 | 85 | 142 | 247 |
| Operating income | (14) | (46) | (80) | (101) | (115) | (173) | (285) |
| Interest expense | – | – | – | – | 1 | 3 | 5 |
| Interest and investment income | – | – | – | 0 | 4 | 24 | 38 |
| Other non-operating income (expense) | (68) | 2 | – | – | – | – | – |
| Income tax expense | – | 0 | – | – | – | – | – |
| Net income | (82) | (44) | (79) | (101) | (112) | (152) | (252) |
| Net income to common shareholders | (82) | (44) | – | – | – | – | – |